Diabetes is now considered an important risk factor for cardiovascular disease, and a complex interplay of pathogenic factors complicates management of both diseases.
Maintaining or increasing physical activity was associated with substantial reductions in CVD mortality risk, in a large cohort of patients with angina pectoris or myocardial infarction.
ACC 2018 A subanalysis of the CANVAS trial showed a treatment benefit of canagliflozin on CVD death and hospitalized HF in patients with T2DM and at CVD risk, especially in those with history of HF.
ACC 2018 In a sub-analysis of the CANTOS trial, canakinumab showed a similar CV event reduction in diabetics and non-diabetics, but did not prevent the progression from pre-diabetes to diabetes.
ACC 2018 The CVD-REAL 2 compared initiation of SGLT-2i with other glucose-lowering drugs in Asia-Pacific, Middle-East and North-America and found generally consistent benefits across regions.
In a data-driven cluster analysis of 6 variables in adult patients with newly diagnosed diabetes, 5 categories of patients were identified with different characteristics and risks of complications.
12-Week treatment with GPR119 agonist DS-8500a lowers HbA1c, FPG and 2hPPG as compared with placebo, albeit to a lesser extend than sitagliptin, but it also lowered total cholesterol, LDL-c and TG.
A genetic predisposition to higher childhood BMI was associated with an increased risk of type 2 diabetes, coronary artery disease, and cardio-metabolic traits in adult life.
In a sub-analysis of the ILLUMINATE study, PCSK9 and Lp(a) levels were dose-dependently increased by atorvastatin in patients at high CV risk.
Data of the PIONEER 1 study show that treatment with the highest tested dose of oral semaglutide in adults with T2DM safely lowered HbA1c by 1.5% at 26 weeks, and yielded a mean 4.1 kg weight loss.
In type 2 diabetic patients with mixed dyslipidemia on maximal statin therapy, the addition of the PCSK9 inhibitor alirocumab is more effective than usual care.
In patients with ischemic stroke ≥ 65 years, diabetes is associated with a higher risk of mortality, recurrent events, HF and hospitalisations.
5 Things a cardiologist needs to know about diabetes Prof Naveed Sattar discusses the value of HbA1c to diagnose T2DM, and how HbA1c levels are related to the risk of developing micro and macrovascular disease and the consequences thereof for choosing a HbA1c therapeutic target.